LTRN
LTRN clinical trials: Lantern Pharma Inc.
Every trial on ClinicalTrials.gov where Lantern Pharma Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 4
- Trials linked
- 3
- As lead sponsor
- 1
- As collaborator
- 1
- Primary completions as lead sponsor, next 90 days
LTRN on the catalyst calendar · LTRN registry changes
- Primary completion Nov 30, 2028Sponsor estimatePhase 1NCT06132503Safety, Pharmacokinetics, and Clinical Activity of LP-284 in Adult Patients With Relapsed or Refractory Lymphomas and Solid TumorsLantern Pharma Inc. · Relapsed or Refractory LymphomasRecruitingLTRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jul 28, 2026Sponsor estimatePhase 1/Phase 2NCT05933265Study of LP-184 in Patients With Advanced Solid TumorsLantern Pharma Inc. · Advanced Solid TumorActive, not recruitingLTRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Dec 2026Sponsor estimatePhase 2NCT05456256A Study of LP-300 With Carboplatin and Pemetrexed in Never Smokers With Advanced Lung AdenocarcinomaLantern Pharma Inc. · Adenocarcinoma of LungRecruitingLTRNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Oct 1, 2021ActualPhase 2NCT03643107Irofulven in AR-targeted and Docetaxel-Pretreated mCRPC Patients With Drug Response Predictor (DRP®)Allarity Therapeutics · Metastatic Castration-Resistant Prostate Cancer PatientsCompletedALLRLeadLTRNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner